Navigation Links
Drug Combo Improves Performance Of Multiple Sclerosis Drug

The performance of the currently used multiple sclerosis drugs can be enhanced by statin therapy, report a group of researchers //. Previously, the same group of researchers had established that stain drugs used for lowering of cholesterol could lower the development of full-blown form of multiple sclerosis.

Although the following results have only been documented in animal models of the disease, so far, the researchers hope that the findings could one day revolutionize treatment of multiple sclerosis, in humans. The results of this promising study can be found in the latest issue of the Journal of Clinical Investigation.

Multiple Sclerosis results from an immune system disorder in which the immune cells attack the myelin sheath (an insulation layer) present in nerve fibers around the spinal cord and brain. Treatment of the disease is based on the use of drugs (Copaxone) that selectively inhibits the destruction of myelin. Copaxone treatment however is effective only in about 30- 35% of the cases.

The researchers, inspired by results of their first study, set out to explore the effectiveness of the new drug combination, Copaxone- Atorvastatin. Addition of high doses of the cholesterol-lowering drug was found to produce a drastic reduction in the inflammation of the central nervous system and elimination of paralysis in animal models designed to mimic human models of MS.

Although Lipitor produces the same effect as Copaxone (through a different mechanism), the clinical and immunological effect may be more pronounced when the drug combination is used. Low doses of Copaxone or Lipitor, on the other hand did not have any beneficial effect with respect to disease reversal.

The researchers have further warned that the effect may not apply to all statin drugs as owing to difference in the ability of the cholesterol lowering drugs to modulate the function of the immune system.

'What we have shown no w is that we have data in an animal model, that when this statin is used in combination with Copaxone, it may augment the activity of Copaxone. That is provocative data supporting human testing of this combination,' said Dr. Scott Zamvil, one of the researchers.

'We don't know if it is effective or not at this stage. Even though they [statins] are relatively safe, we are speaking of higher doses. There is a lot of interest in statins and they are generally well tolerated, but we are cautioning people not to rely on statins for multiple sclerosis treatment', cautioned Dr. Jeffrey Cohen, a leading neurologist, Cleveland Clinic.


'"/>




Related medicine news :

1. Drug Combo Works Better for children with ADHD, Tics
2. Scanning Combo Helps Detect Lung Cancer
3. Relief From Asthma With New Combo Therapy
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
6. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
7. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
8. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
9. Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings
10. Fuzeon and MK-0518 Combo Holds Promise For HIV
11. Germ - Chemo Combo Fights Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in ... responds to and which He does not. Yisrayl says with so many titles and ... true name, but he says with a little Scripture, backed with a lot of research, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Rob Lowe is ... now he has leant his presence to an educational purpose as the host of ... important one being cancer. In a recent episode, the series focuses on thyroid cancer. ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... YORK , April 19, 2017 ... This report on the prostate cancer therapeutics ... the global market. Increasing prevalence of prostate cancer, ... innovation in the development of new drugs & ... prostate cancer drug due to lesser side effects ...
Breaking Medicine Technology: